Carregant...
Is It Time to Inform This Patient that Further Antineoplastic Drug Therapy Will Not Be of Clinical Value?
A woman with heavy pre-treated ovarian cancer sought consultation regarding additional treatments. The case raises the vexing question of whether there may be a time in the course of the disease process where it is most appropriate to state further anti-neoplastic therapy will not be of clinical uti...
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
S. Karger AG
2010
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2918845/ https://ncbi.nlm.nih.gov/pubmed/20740161 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000295905 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|